Close Menu

Spanish National Research Council

Using genomic data for hundreds of ancient Europeans, research teams retraced the spread of the Beaker complex culture as well as interactions between pastoralists and hunter-gatherers.

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

NEW YORK (GenomeWeb News) – Some cases of premature ovarian failure and related infertility may be due to mutations affecting proteins involved in meiosis, according to a pair of exome sequencing reports published in the New England Journal of Medicine yesterday.

NEW YORK (GenomeWeb Daily News) – An international team of researchers sequenced the genome and characterized a handful of alleles from a Mesolithic skeleton dating back some 7,000 years.

Qiagen will distribute a new amplification buffer from Sygnis Pharma under a licensing agreement between the companies, Sygnis said today.

German pharmaceutical company Sygnis Pharma said today that it is acquiring X-Pol Biotech, a subsidiary of Spanish biotechnology holding company Genetrix, in a bid to further develop and market X-Pol's DNA sequencing technologies and products, including its DNA polymerase technol

An ethics committee at the Spanish National Research Council is reportedly calling for researchers to retract a paper published last year describing an array-based approach for measuring metabolite levels and enzyme activity.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.